NCT03859219View on ClinicalTrials.gov

A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy Japanese, Chinese and Caucasian Study Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

March 18, 2019

Primary Completion Date

April 28, 2020

Study Completion Date

April 28, 2020

Conditions
Healthy-volunteers
Interventions
DRUG

Rozanolixizumab

"* Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion"

DRUG

Placebo

"* Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion"

Trial Locations (1)

Unknown

UP0060 1, London

All Listed Sponsors
lead

UCB Biopharma S.P.R.L.

INDUSTRY

NCT03859219 - A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy Japanese, Chinese and Caucasian Study Participants | Biotech Hunter | Biotech Hunter